• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

硼替佐米联合CHOP方案治疗鼻型外周T细胞淋巴瘤可快速缓解

Rapid Remission in Peripheral T-Cell Lymphoma of the Nasal Type by the Bortezomib plus CHOP Therapy.

作者信息

Xue Li-Jun, Mao Xiao-Bei, Liu Xiao-Bei, Su Quan-Sheng, Yu Hong-Ju, Yang Ji-Hong

机构信息

Department of Oncology and Hematology, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhong-shan Road, Nanjing, Jiangsu Province 210002, China.

出版信息

Case Rep Med. 2010;2010:403237. doi: 10.1155/2010/403237. Epub 2010 Dec 26.

DOI:10.1155/2010/403237
PMID:21209804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3014791/
Abstract

Peripheral T-cell lymphoma (PTCL) is rare and difficult to treat for its high relapse rate. The authors report a case of PTCL of the skin, regarding which clinical and pathological features, treatment, and prognosis were discussed. A 66-year-old woman was admitted with complaints of enlarging erythematous noduloplaques on the right anterior tibial skin for one year and similar lesions on the left for 6 months. Surgical resection of right leg lesion and biopsy of enlarged inguinal lymph nodes histologically indicated a PTCL of the nasal type. The patient was treated by CHOP plus bortezomib, reached complete remission just after two courses of chemotherapy and then received another two as consolidation. The patient remained in remission for 11 months until local relapse. As for cutaneous lesions, detailed lymph node examination and prompt tissue biopsy are judicious choices prior to any medical management. The chemotherapy consisting of bortezomib and CHOP is safe and efficient in PTCL of the skin.

摘要

外周T细胞淋巴瘤（PTCL）较为罕见，且因其高复发率而难以治疗。作者报告了1例皮肤PTCL病例，并对其临床和病理特征、治疗及预后进行了讨论。一名66岁女性因右胫前皮肤出现逐渐增大的红斑性结节斑块1年、左侧出现类似病变6个月而入院。对右腿病变进行手术切除，并对肿大的腹股沟淋巴结进行活检，组织学检查显示为鼻型PTCL。该患者接受了CHOP方案联合硼替佐米治疗，仅在两个化疗疗程后即达到完全缓解，随后又接受了两个疗程的巩固治疗。患者缓解了11个月，直至局部复发。对于皮肤病变，在进行任何医学处理之前，详细的淋巴结检查和及时的组织活检是明智的选择。由硼替佐米和CHOP组成的化疗方案在皮肤PTCL中安全有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/3014791/c82e0311fcde/CRIM2010-403237.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/3014791/e6a69d6acc92/CRIM2010-403237.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/3014791/03d3c5841932/CRIM2010-403237.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/3014791/c82e0311fcde/CRIM2010-403237.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/3014791/e6a69d6acc92/CRIM2010-403237.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/3014791/03d3c5841932/CRIM2010-403237.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/3014791/c82e0311fcde/CRIM2010-403237.003.jpg

相似文献

1
Rapid Remission in Peripheral T-Cell Lymphoma of the Nasal Type by the Bortezomib plus CHOP Therapy.硼替佐米联合CHOP方案治疗鼻型外周T细胞淋巴瘤可快速缓解
Case Rep Med. 2010;2010:403237. doi: 10.1155/2010/403237. Epub 2010 Dec 26.
2
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.硼替佐米联合 CHOP 方案作为 III/IV 期外周 T 细胞淋巴瘤患者的一线治疗：一项多中心、单臂、Ⅱ期临床试验。
Eur J Cancer. 2012 Nov;48(17):3223-31. doi: 10.1016/j.ejca.2012.06.003. Epub 2012 Jul 4.
3
Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature.基于硼替佐米的化疗方案治疗难治性血管免疫母细胞性T细胞淋巴瘤：一例病例报告及文献综述
Oncol Lett. 2016 Mar;11(3):2310-2314. doi: 10.3892/ol.2016.4213. Epub 2016 Feb 9.
4
Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP.一名72岁原发性眼睑弥漫性外周T细胞淋巴瘤（非特指型）患者在接受依托泊苷联合COP化疗后实现临床缓解
Diagnostics (Basel). 2020 Aug 24;10(9):629. doi: 10.3390/diagnostics10090629.
5
Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).成功实施基于基因组的化疗耐药外周 T 细胞淋巴瘤（PTCL）治疗。
Cancer Biol Ther. 2019;20(3):247-251. doi: 10.1080/15384047.2018.1523857. Epub 2018 Oct 11.
6
[Follicular lymphoma: first - line selection criteria of treatment].[滤泡性淋巴瘤：一线治疗选择标准]
Ter Arkh. 2019 Aug 15;91(8):75-83. doi: 10.26442/00403660.2019.08.000388.
7
Clinical features and treatment outcomes of peripheral T-cell lymphoma in children. A current data report from Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG).儿童外周T细胞淋巴瘤的临床特征与治疗结果。波兰儿童白血病/淋巴瘤研究组（PPLLSG）的一份最新数据报告。
Adv Med Sci. 2016 Sep;61(2):311-316. doi: 10.1016/j.advms.2016.03.002. Epub 2016 Mar 21.
8
Synchronous Gastric Carcinoma and Nodal Malignant Lymphoma: A Rare Case Report and Literature Review.同步性胃癌与淋巴结恶性淋巴瘤：一例罕见病例报告及文献复习
Case Rep Oncol. 2010 Jul 10;3(2):223-230. doi: 10.1159/000317603.
9
Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.外周T细胞淋巴瘤患者在接受一线强化序贯化疗联合自体干细胞移植后的长期生存。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):63-6. doi: 10.5507/bp.2009.011.
10
Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report.聚乙二醇化脂质体包裹阿霉素治疗皮肤复合性淋巴瘤：一例报告
Medicine (Baltimore). 2016 Oct;95(43):e4796. doi: 10.1097/MD.0000000000004796.

本文引用的文献

1
Comparison of four prognostic scores in peripheral T-cell lymphoma.外周 T 细胞淋巴瘤四种预后评分的比较。
Ann Oncol. 2011 Feb;22(2):397-404. doi: 10.1093/annonc/mdq359. Epub 2010 Jul 14.
2
The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project.
Ann Oncol. 2009 Apr;20(4):715-21. doi: 10.1093/annonc/mdn696. Epub 2009 Jan 15.
3
Prognosis and primary therapy in peripheral T-cell lymphomas.外周T细胞淋巴瘤的预后与初始治疗
Hematology Am Soc Hematol Educ Program. 2008:280-8. doi: 10.1182/asheducation-2008.1.280.
4
Pathobiology and molecular profiling of peripheral T-cell lymphomas.外周T细胞淋巴瘤的病理生物学与分子特征分析
Hematology Am Soc Hematol Educ Program. 2008:272-9. doi: 10.1182/asheducation-2008.1.272.
5
Mechanisms of proteasome inhibitor action and resistance in cancer.蛋白酶体抑制剂在癌症中的作用及耐药机制。
Drug Resist Updat. 2008 Aug-Oct;11(4-5):164-79. doi: 10.1016/j.drup.2008.08.002. Epub 2008 Sep 24.
6
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.蛋白酶体抑制剂硼替佐米联合CHOP方案用于晚期侵袭性T细胞或NK/T细胞淋巴瘤患者的I期研究。
Ann Oncol. 2008 Dec;19(12):2079-83. doi: 10.1093/annonc/mdn431. Epub 2008 Aug 9.
7
Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified".“外周T细胞淋巴瘤，非特指型”患者的临床特征及预后因素
Ann Hematol. 2009 Feb;88(2):111-9. doi: 10.1007/s00277-008-0544-2. Epub 2008 Jul 22.
8
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.国际外周T细胞和自然杀伤/T细胞淋巴瘤研究：病理结果与临床结局
J Clin Oncol. 2008 Sep 1;26(25):4124-30. doi: 10.1200/JCO.2008.16.4558. Epub 2008 Jul 14.
9
Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.一名肝脾γδT细胞淋巴瘤患者接受硼替佐米和大剂量类CHOP化疗后进行自体外周干细胞移植，实现长期缓解。
Ann Hematol. 2008 Dec;87(12):1023-4. doi: 10.1007/s00277-008-0523-7. Epub 2008 Jun 28.
10
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.蛋白酶体抑制剂硼替佐米用于复发或难治性皮肤T细胞淋巴瘤患者的II期试验。
J Clin Oncol. 2007 Sep 20;25(27):4293-7. doi: 10.1200/JCO.2007.11.4207. Epub 2007 Aug 20.